Complete Metabolic Response Assessed by FDG PET/CT to FOLFIRI-Aflibercept in Second-Line Treatment of Metastatic Colorectal Cancer

被引：2

作者：

Amrane, Karim ^{[1
]}

Ollivier, Luc ^{[2
]}

Salaun, Pierre-Yves ^{[3
,4
]}

Metges, Jean-Philippe ^{[1
]}

Abgral, Ronan ^{[3
,4
]}

机构：

[1] Univ Hosp Brest, Dept Oncol, 2 Ave Foch, F-29609 Brest, France

[2] Univ Hosp Brest, Dept Radiotherapy, Brest, France

[3] Univ Hosp Brest, Dept Nucl Med, Brest, France

[4] Bretagne Loire Univ, EA GETBO 3878, IFR 148, Brest, France

来源：

CLINICAL NUCLEAR MEDICINE | 2019年 / 44卷 / 07期

关键词：

mCRC; FOLFIRI-aflibercept; FDG PET; CT; BEVACIZUMAB; OXALIPLATIN; PATIENT; FOLFOX;

D O I：

10.1097/RLU.0000000000002611

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

FOLFIRI-aflibercept chemotherapy is indicated in second-line treatment of metastatic colorectal cancer (mCRC) after progression under FOLFOX (+/- bevacizumab). Nevertheless, its proven therapeutic efficacy in clinical trials was based on partial responses. And to date, only 2 cases of complete response assessed by CT were reported in literature. We report a complete metabolic response assessed by FDG PET/CT in a 50-year-old woman with mCRC treated by FOLFIRI-aflibercept. This also confirms that FDG PET/CT is emerging as a useful approach for therapeutic assessment of targeted drugs in mCRC.

引用

页码：578 / 579

页数：2

共 50 条

[21] Impact of omitting fluorouracil from FOLFIRI plus bevacizumab in second-line treatment of metastatic colorectal cancer
Matsubara, Yuki
Masuishi, Toshiki
Ogata, Takatsugu
Nakazawa, Taiko
Kato, Kyoko
Nozawa, Kazuki
Narita, Yukiya
Honda, Kazunori
Bando, Hideaki
Kadowaki, Shigenori
Ando, Masashi
Tajika, Masahiro
Muro, Kei
ANNALS OF ONCOLOGY, 2021, 32 : S321 - S321
[22] Second-line treatment of patients with metastatic colorectal cancer
Rougier, P
Lepere, C
SEMINARS IN ONCOLOGY, 2005, 32 (06) : S48 - S54
[23] Metastatic colorectal Cancer Ramucirumab plus FOLFIRI as Second Line Treatment
Lichert, Frank
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (10): : 1145 - 1145
[24] Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)
Riechelmann, Rachel P.
Srimuninnimit, Vichien
Bordonaro, Roberto
Kavan, Petr
Di Bartolomeo, Maria
Maiello, Evaristo
Cicin, Irfan
Garcia-Alfonso, Pilar
Chau, Ian
Fedyanin, Mikhail Y.
Fernandez Martos, Carlos
Ter-Ovanesov, Mikhail
Peeters, Marc
Ko, Yoo-Joung
Yalcin, Suayib
Karthaus, Meinolf
Aparicio, Jorge
Heinemann, Volker
Picard, Pascaline
Bury, Denise
Drea, Edward
Sobrero, Alberto
CLINICAL COLORECTAL CANCER, 2019, 18 (03) : 183 - +
[25] Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group
Erol, Cihan
Sendur, Mehmet Ali Nahit
Bilgetekin, Irem
Garbioglu, Duygu Bayir
Hamdard, Jamshid
Akbas, Sinem
Hizal, Mutlu
Arslan, Cagatay
Sevinc, Alper
Kucukarda, Ahmet
Erdem, Dilek
Kahraman, Seda
Cakir, Emre
Demirkiran, Aykut
On, Sercan
Dogan, Izzet
Erdogan, Atike Pinar
Koca, Sinan
Kubilay, Pinar
Eren, Orhan Onder
Cilbir, Ebru
Celik, Emir
Araz, Murat
Ozyukseler, Deniz Tataroglu
Yildirim, Mahmut Emre
Bahceci, Aykut
Taskaynatan, Halil
Oyman, Abdilkerim
Deniz, Gulhan Ipek
Menekse, Serkan
Kut, Engin
Gulmez, Ahmet
Sakin, Abdullah
Nayir, Erdinc
Acar, Ramazan
Sen, Erdem
Inal, Ali
Turhal, Serdar
Kaya, Ali Osman
Paydas, Semra
Tastekin, Didem
Hacibekiroglu, Ilhan
Cincin, Irfan
Bilici, Ahmet
Mandel, Nil Molinas
Dede, Didem Sener
Akinci, Muhammed Bulent
Oksuzoglu, Berna
Uncu, Dogan
Yalcin, Bulent
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (09) : S347 - S353
[26] EFICACY AND SAFETY OF FOLFIRI-BEVACIZUMAB FOR THE SECOND-LINE TREATMENT OF METASTATIC COLORECTAL CARCINOMA
Odabas, H.
Ozdemir, N.
Oksuzoglu, B.
Abali, H.
Kos, F. T.
Babacan, N.
Civelek, B.
Uncu, D.
Zengin, N.
ANNALS OF ONCOLOGY, 2010, 21 : 218 - 218
[27] Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept
Yamada, Yunami
Matsuhashi, Nobuhisa
Fujii, Hironori
Makiyama, Akitaka
Iihara, Hirotoshi
Takahashi, Takao
Watanabe, Daichi
Kiyama, Shigeru
Kobayashi, Ryo
Suzuki, Akio
Yoshida, Kazuhiro
ANTICANCER RESEARCH, 2021, 41 (01) : 533 - 541
[28] Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients
de Toro Carmena, M.
Ortega Moran, I.
Garcia Adrian, S.
Castanon Lopez, C.
Molina Villaverde, R.
Marrupe Gonzalez, D.
Lopez Munoz, A.
Alcaraz Nunes, D.
Diaz Beveridge, R.
Lopez Alfonso, A.
Garcia Paredes, B.
Fernandez Montes, A.
Soriano Rodriguez, M.
Encinas Garcia, S.
Alcaide Garcia, I.
Pericay Pijaume, C.
Macarulla Mercade, C.
Redriguez-Salas, N.
Garcia Alfonso, P.
Munoz Martin, A.
ANNALS OF ONCOLOGY, 2019, 30
[29] Efficacy of ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer
Katata, Y.
Nagasaka, T.
Tanioka, H.
Nyuya, A.
Toshima, T.
Mori, Y.
Shigeyasu, K.
Okawaki, M.
Yamamura, M.
Tsuruta, A.
Ueno, T.
Yamaguchi, Y.
ANNALS OF ONCOLOGY, 2018, 29 : 33 - 33
[30] Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial
Garcia Alfonso, P.
Elez Fernandez, M. E.
Soto Alsar, J.
Paez, D.
Fernandez Montes, A.
Grana Suarez, B.
Salud, A.
Yubero Esteban, A.
Gomez Espana, M. A.
Macias Declara, I.
Quintero Aldana, G. A.
Lopez Lopez, C.
Fernandez Rodriguez, T.
Gravalos Castro, M. C.
Gonzalez-Flores, E.
Guix Arnau, M.
Paredes, B. Garcia
Zoilo, J. J. Reina
Varela, J. Sastre
Aguilar, E. Aranda
ANNALS OF ONCOLOGY, 2023, 34 : S416 - S417

← 1 2 3 4 5 →